» Articles » PMID: 23995785

Activation of Akt Signaling in Prostate Induces a TGFβ-mediated Restraint on Cancer Progression and Metastasis

Overview
Journal Oncogene
Date 2013 Sep 3
PMID 23995785
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Mutations in the PTEN tumor suppressor gene are found in a high proportion of human prostate cancers, and in mice, Pten deletion induces high-grade prostate intraepithelial neoplasia (HGPIN). However, progression from HGPIN to invasive cancer occurs slowly, suggesting that tumorigenesis is subject to restraint. We show that Pten deletion, or constitutive activation of the downstream kinase AKT, activates the transforming growth factor (TGF)β pathway in prostate epithelial cells. TGFβ signaling is known to have a tumor suppressive role in many cancer types, and reduced expression of TGFβ receptors correlates with advanced human prostate cancer. We demonstrate that in combination either with loss of Pten or expression of constitutively active AKT1, inactivation of TGFβ signaling by deletion of the TGFβ type II receptor gene relieves a restraint on tumorigenesis. This results in rapid progession to lethal prostate cancer, including metastasis to lymph node and lung. In prostate epithelium, inactivation of TGFβ signaling alone is insufficient to initiate tumorigenesis, but greatly accelerates cancer progression. The activation of TGFβ signaling by Pten loss or AKT activation suggests that the same signaling events that have key roles in tumor initiation also induce the activity of a pathway that restrains disease progression.

Citing Articles

Network pharmacology and bioinformatics analysis identifies potential therapeutic targets of against COVID-19/LUSC.

Wu W, Jiao X, Song W, Wu P, Xiao P, Huang X Front Endocrinol (Lausanne). 2023; 14:1187882.

PMID: 37347115 PMC: 10281056. DOI: 10.3389/fendo.2023.1187882.


Establishment and characterization of prostate organoids from treatment-naïve patients with prostate cancer.

Cheaito K, Bahmad H, Hadadeh O, Msheik H, Monzer A, Ballout F Oncol Lett. 2021; 23(1):6.

PMID: 34820005 PMC: 8607232. DOI: 10.3892/ol.2021.13124.


Post-Transcriptional Regulation of PARP7 Protein Stability Is Controlled by Androgen Signaling.

Kamata T, Yang C, Melhuish T, Frierson Jr H, Wotton D, Paschal B Cells. 2021; 10(2).

PMID: 33572475 PMC: 7916378. DOI: 10.3390/cells10020363.


Opposing roles and potential antagonistic mechanism between TGF-β and BMP pathways: Implications for cancer progression.

Ning J, Zhao Y, Ye Y, Yu J EBioMedicine. 2019; 41:702-710.

PMID: 30808576 PMC: 6442991. DOI: 10.1016/j.ebiom.2019.02.033.


Deregulation of Negative Controls on TGF-β1 Signaling in Tumor Progression.

Tang J, Gifford C, Samarakoon R, Higgins P Cancers (Basel). 2018; 10(6).

PMID: 29799477 PMC: 6025439. DOI: 10.3390/cancers10060159.


References
1.
Massague J, Seoane J, Wotton D . Smad transcription factors. Genes Dev. 2005; 19(23):2783-810. DOI: 10.1101/gad.1350705. View

2.
Ikushima H, Miyazono K . TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer. 2010; 10(6):415-24. DOI: 10.1038/nrc2853. View

3.
Kim J, Roh M, Doubinskaia I, Algarroba G, Eltoum I, Abdulkadir S . A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53. Oncogene. 2011; 31(3):322-32. PMC: 3179816. DOI: 10.1038/onc.2011.236. View

4.
Levy L, Hill C . Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev. 2005; 17(1-2):41-58. DOI: 10.1016/j.cytogfr.2005.09.009. View

5.
Suzuki A, Yamaguchi M, Ohteki T, Sasaki T, Kaisho T, Kimura Y . T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity. 2001; 14(5):523-34. DOI: 10.1016/s1074-7613(01)00134-0. View